Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81112 | 0.90 | KDM4E (0.63) | POLBKDM4ECA2ATMTNKS2 | |
| Alcohol SCHEMBL15062546 | 0.87 | KDM4E (0.59) | POLBKDM4ECA2ATMTNKS2 | |
| SCHEMBL4860600 | 0.85 | KDM4E (0.61) | POLBKDM4ECA2ATMTNKS2 | |
| SCHEMBL7320148 | 0.85 | LMNA (0.50) | POLBKDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9506664 | 0.83 | KDM4E (0.59) | POLBKDM4ECA2ATMTNKS2 | |
| SCHEMBL7184663 | 0.83 | KDM4E (0.59) | POLBKDM4ECA2ATMTNKS2 | |
| SCHEMBL2802611 | 0.83 | KDM4E (0.59) | POLBKDM4ECA2ATMTNKS2 | |
| SCHEMBL6572223 | 0.83 | CA2 (0.54) | POLBKDM4ECA12CA1CA2 | |
| SCHEMBL7156624 | 0.82 | PLAAT3 (0.56) | POLBKDM4ECA12CA1CA2 | |
| SCHEMBL10415400 | 0.81 | CA2 (0.52) | POLBKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | BIOPROJET (FR) | 2008-07-31 | — | — | US | disclosed |
| EP-1874747-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117611-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717233-A1 | Histamine H3-receptor ligands and their therapeutic application | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-5276060-A | Methods of treating tumors with compositions of catecholic butanes | BLOCK/CHEMEX, G.P. (US) | 1994-01-04 | — | — | US | disclosed |
| EP-0288534-B1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-12-18 | — | — | EP | disclosed |
| US-5008294-A | Topical administration | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-04-16 | — | — | US | disclosed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | disclosed |
| US-4880637-A | ALCOHOLS, ETHERS OR ESTERS, AS ANTITUMOR AGENTS, SKIN DISORDERS | CHEMEX PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0288534-A4 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1989-02-23 | — | — | EP | disclosed |
| EP-0297733-A2 | Pharmaceutical compositions comprising catecholic butanes | BLOCK DRUG COMPANY, INC. (US) | 1989-01-04 | — | — | EP | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| EP-0288534-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988003806-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003026-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | HRH3, HRH4, HRH1 | POLB 4442/4885KDM4E 1619/4885CA12 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.